[HTML][HTML] Introduction of a xenogeneic gene via hematopoietic stem cells leads to specific tolerance in a rhesus monkey model

DA Heim, Y Hanazono, N Giri, T Wu, R Childs… - Molecular Therapy, 2000 - cell.com
DA Heim, Y Hanazono, N Giri, T Wu, R Childs, SE Sellers, L Muul, ME Metzger…
Molecular Therapy, 2000cell.com
Host immune responses against foreign transgenes may be a major obstacle to successful
gene therapy. To clarify the impact of an immune response to foreign transgene products on
the survival of genetically modified cells, we studied the in vivo persistence of cells
transduced with a vector expressing a foreign transgene compared to cells transduced with
a nonexpressing vector in the clinically predictive rhesus macaque model. We constructed
retroviral vectors containing the neomycin phosphotransferase gene (neo) sequences …
Abstract
Host immune responses against foreign transgenes may be a major obstacle to successful gene therapy. To clarify the impact of an immune response to foreign transgene products on the survival of genetically modified cells, we studied the in vivo persistence of cells transduced with a vector expressing a foreign transgene compared to cells transduced with a nonexpressing vector in the clinically predictive rhesus macaque model. We constructed retroviral vectors containing the neomycin phosphotransferase gene (neo) sequences modified to prevent protein expression (nonexpressing vectors). Rhesus monkey lymphocytes or hematopoietic stem cells (HSCs) were transduced with nonexpressing and neo-expressing vectors followed by reinfusion, and their in vivo persistence was studied. While lymphocytes transduced with a nonexpressing vector could be detected for more than 1 year, lymphocytes transduced with a neo-expressing vector were no longer detectable within several weeks of infusion. However, five of six animals transplanted with HSCs transduced with nonexpression or neo-expression vectors, and progeny lymphocytes marked with either vector persisted for more than 2 years. Furthermore, in recipients of transduced HSCs, infusion of mature lymphocytes transduced with a second neo-expressing vector did not result in elimination of the transduced lymphocytes. Our data show that introduction of a xenogeneic gene via HSCs induces tolerance to the foreign gene products. HSC gene therapy is therefore suitable for clinical applications where long-term expression of a therapeutic or foreign gene is required.
cell.com